questionsmedicales.fr
Bactéries
Proteobacteria
Gammaproteobacteria
Vibrionaceae
Vibrio
Vibrio : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vibrio : Questions médicales les plus fréquentes",
"headline": "Vibrio : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vibrio"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vibrionaceae",
"url": "https://questionsmedicales.fr/mesh/D014737",
"about": {
"@type": "MedicalCondition",
"name": "Vibrionaceae",
"code": {
"@type": "MedicalCode",
"code": "D014737",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio alginolyticus",
"alternateName": "Vibrio alginolyticus",
"url": "https://questionsmedicales.fr/mesh/D044149",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio alginolyticus",
"code": {
"@type": "MedicalCode",
"code": "D044149",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.030"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae",
"alternateName": "Vibrio cholerae",
"url": "https://questionsmedicales.fr/mesh/D014734",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae",
"code": {
"@type": "MedicalCode",
"code": "D014734",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae non-O1",
"alternateName": "Vibrio cholerae non-O1",
"url": "https://questionsmedicales.fr/mesh/D044163",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae non-O1",
"code": {
"@type": "MedicalCode",
"code": "D044163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O1",
"alternateName": "Vibrio cholerae O1",
"url": "https://questionsmedicales.fr/mesh/D041241",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O1",
"code": {
"@type": "MedicalCode",
"code": "D041241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O139",
"alternateName": "Vibrio cholerae O139",
"url": "https://questionsmedicales.fr/mesh/D041242",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O139",
"code": {
"@type": "MedicalCode",
"code": "D041242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Vibrio mimicus",
"alternateName": "Vibrio mimicus",
"url": "https://questionsmedicales.fr/mesh/D044164",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio mimicus",
"code": {
"@type": "MedicalCode",
"code": "D044164",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio parahaemolyticus",
"alternateName": "Vibrio parahaemolyticus",
"url": "https://questionsmedicales.fr/mesh/D014736",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio parahaemolyticus",
"code": {
"@type": "MedicalCode",
"code": "D014736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.590"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio vulnificus",
"alternateName": "Vibrio vulnificus",
"url": "https://questionsmedicales.fr/mesh/D041261",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio vulnificus",
"code": {
"@type": "MedicalCode",
"code": "D041261",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vibrio",
"alternateName": "Vibrio",
"code": {
"@type": "MedicalCode",
"code": "D014733",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jaime Martinez-Urtaza",
"url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Jessica L Jones",
"url": "https://questionsmedicales.fr/author/Jessica%20L%20Jones",
"affiliation": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136."
}
},
{
"@type": "Person",
"name": "William C Walton",
"url": "https://questionsmedicales.fr/author/William%20C%20Walton",
"affiliation": {
"@type": "Organization",
"name": "2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA."
}
},
{
"@type": "Person",
"name": "Julia C van Kessel",
"url": "https://questionsmedicales.fr/author/Julia%20C%20van%20Kessel",
"affiliation": {
"@type": "Organization",
"name": "Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu."
}
},
{
"@type": "Person",
"name": "Blake Ushijima",
"url": "https://questionsmedicales.fr/author/Blake%20Ushijima",
"affiliation": {
"@type": "Organization",
"name": "Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.",
"datePublished": "2022-11-04",
"url": "https://questionsmedicales.fr/article/36332914",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1124/dmd.122.001107"
}
},
{
"@type": "ScholarlyArticle",
"name": "Carbon Dots with Guanidinium and Amino Acid Functional Groups for Targeted Small Interfering RNA Delivery toward Tumor Gene Therapy.",
"datePublished": "2023-02-25",
"url": "https://questionsmedicales.fr/article/36840641",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/smll.202207204"
}
},
{
"@type": "ScholarlyArticle",
"name": "Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?",
"datePublished": "2023-04-01",
"url": "https://questionsmedicales.fr/article/37011722",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejphar.2023.175699"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.",
"datePublished": "2022-07-20",
"url": "https://questionsmedicales.fr/article/35870702",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jhep.2022.07.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tetrahedral Framework Nucleic Acids Based Small Interfering RNA Targeting Receptor for Advanced Glycation End Products for Diabetic Complications Treatment.",
"datePublished": "2023-09-26",
"url": "https://questionsmedicales.fr/article/37751401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acsnano.3c06999"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Bactéries",
"item": "https://questionsmedicales.fr/mesh/D001419"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020560"
},
{
"@type": "ListItem",
"position": 4,
"name": "Gammaproteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020563"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vibrionaceae",
"item": "https://questionsmedicales.fr/mesh/D014737"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014733"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vibrio - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vibrio",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vibrio",
"description": "Comment diagnostiquer une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes tests sérologiques sont-ils utiles ?\nPeut-on diagnostiquer Vibrio par PCR ?\nQuels symptômes orientent vers un diagnostic de Vibrio ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=RNA,+Small+Interfering&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vibrio",
"description": "Quels sont les symptômes d'une infection à Vibrio ?\nLa diarrhée est-elle toujours présente ?\nLes infections à Vibrio causent-elles de la fièvre ?\nY a-t-il des symptômes graves associés ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=RNA,+Small+Interfering&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vibrio",
"description": "Comment prévenir les infections à Vibrio ?\nLe lavage des mains est-il important ?\nLes vaccinations existent-elles contre Vibrio ?\nFaut-il éviter certains aliments ?\nLes voyages augmentent-ils le risque d'infection ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=RNA,+Small+Interfering&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vibrio",
"description": "Quel est le traitement principal pour Vibrio ?\nQuels antibiotiques sont efficaces contre Vibrio ?\nLa réhydratation est-elle toujours nécessaire ?\nLes traitements sont-ils différents selon le type de Vibrio ?\nLes probiotiques aident-ils dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=RNA,+Small+Interfering&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vibrio",
"description": "Quelles complications peuvent survenir avec Vibrio ?\nLa déshydratation est-elle une complication fréquente ?\nLes infections à Vibrio peuvent-elles être mortelles ?\nY a-t-il des risques pour les personnes immunodéprimées ?\nLes infections cutanées sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=RNA,+Small+Interfering&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vibrio",
"description": "Quels sont les principaux facteurs de risque pour Vibrio ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection ?\nLes personnes vivant près de l'eau sont-elles plus exposées ?\nLes voyages dans des zones endémiques sont-ils risqués ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=RNA,+Small+Interfering&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection à Vibrio ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour identifier Vibrio ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture et des tests biochimiques spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les tests sérologiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques ne sont généralement pas utilisés pour Vibrio."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer Vibrio par PCR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons."
}
},
{
"@type": "Question",
"name": "Quels symptômes orientent vers un diagnostic de Vibrio ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection à Vibrio ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre."
}
},
{
"@type": "Question",
"name": "La diarrhée est-elle toujours présente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio causent-elles de la fièvre ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes graves associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections à Vibrio ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains."
}
},
{
"@type": "Question",
"name": "Le lavage des mains est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes."
}
},
{
"@type": "Question",
"name": "Les vaccinations existent-elles contre Vibrio ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains aliments ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'infection ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour Vibrio ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels antibiotiques sont efficaces contre Vibrio ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "La réhydratation est-elle toujours nécessaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents selon le type de Vibrio ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection."
}
},
{
"@type": "Question",
"name": "Les probiotiques aident-ils dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Vibrio ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale."
}
},
{
"@type": "Question",
"name": "La déshydratation est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio peuvent-elles être mortelles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour les personnes immunodéprimées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées sont à risque accru de complications graves."
}
},
{
"@type": "Question",
"name": "Les infections cutanées sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour Vibrio ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio."
}
},
{
"@type": "Question",
"name": "Le diabète augmente-t-il le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut augmenter le risque d'infections graves à Vibrio."
}
},
{
"@type": "Question",
"name": "Les personnes vivant près de l'eau sont-elles plus exposées ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones endémiques sont-ils risqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection."
}
}
]
}
]
}
RNA-based oligonucleotide therapeutics are revolutionizing drug development for disease treatment. This class of therapeutics differs from small molecules and protein therapeutics in various ways, inc...
Small interfering RNA (siRNA)-based gene therapy represents a promising strategy for tumor treatment. Novel gene vectors that can achieve targeted delivery of siRNA to the tumor cells without causing ...
Colorectal cancer (CRC) is the third most common cancer and the leading cause of gastrointestinal cancer death. 90% of people diagnosed with colorectal cancer are over the age of 50; nevertheless, the...
RNA interference therapy has been shown to reduce hepatitis B surface antigen (HBsAg) levels in preclinical models, which could confer functional cure in patients with chronic hepatitis B. This phase ...
Treatment-naïve and NA-suppressed patients received 3 subcutaneous JNJ-3989 doses every week (QW; 100, 200, or 300 mg), 2 weeks (Q2W; 100 mg) or 4 weeks (Q4W; 25, 50, 100, 200, 300, or 400 mg), or JNJ...
Eighty-four patients were recruited. All treatments were well tolerated, with all 5 serious adverse events considered unrelated to study drugs. JNJ-3989 100 to 400 mg Q4W resulted in HBsAg reductions ...
JNJ-3989 plus an NA, with/without JNJ-6379, was well tolerated and resulted in HBsAg reductions up to 336 days after the last JNJ-3989 Q4W dose....
NCT03365947....
Hepatitis B virus affects people's livers and produces particles called hepatitis B surface antigen (HBsAg) that damage a person's liver and can help the virus infect a person for a long time, known a...
Complications arising from diabetes can threaten multiple organs. Advanced glycation end products (AGEs) play a significant role in inducing these complications. Highly processed diets and hyperglycem...
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial sy...
The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting...
Using Pubmed, Embase, Cochrane Library and clinicaltrials.gov until April 2023, we extracted randomized controlled trials (RCTs) of PCSK9 inhibitors (Evolocumab, Alirocumab) and siRNA therapy (Inclisi...
In all, 54 studies with 87,669 participants (142,262 person-years) met criteria for inclusion. LDL-c percent change was reported in 47 studies (n = 62,634) evaluating two PCSK9 inhibitors and siRNA th...
PCSK9 inhibitors (Evolocumab, Alirocumab) and siRNA therapy (Inclisiran) significantly reduced LDL-c by >40% in high-risk individuals. Additionally, both Alirocumab and Evolocumab reduced the risk of ...
The PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) enzyme interferes with the metabolism of low-density lipoprotein (LDL) cholesterol. Inhibition of PCSK9 results in lower LDL cholesterol level...
There is overwhelming clinical and genetic evidence supporting the concept that low-density-lipoprotein cholesterol should be as low as possible for as long as possible in patients at very high cardio...
To date, no medical therapy can slow the progression of aortic stenosis. Fibrocalcific stenosis is the most frequent form in the general population and affects about 6% of the elderly population. Over...
MicroRNAs (miRNAs) and small interfering RNAs (siRNAs) are loaded into Argonaute (AGO) proteins, forming RNA-induced silencing complexes (RISCs). The assembly process establishes the seed, central, 3'...